Ranibizumab Intraocular and Zoladex (Goserelin Implant 3.6 mg)
Determining the interaction of Ranibizumab Intraocular and Zoladex (Goserelin Implant 3.6 mg) and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: ranibizumab ophthalmic
Brand name: Lucentis
Synonyms: Ranibizumab (ophthalmic), Ranibizumab
Generic Name: goserelin
Brand name: Zoladex
Synonyms: Zoladex
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ranibizumab Intraocular-Zoladex 3-Month
- Ranibizumab Intraocular-Zoladex Implant
- Ranibizumab Intraocular-Zolate
- Ranibizumab Intraocular-Zoledronic acid
- Ranibizumab Intraocular-Zoledronic Acid (Bone Health)
- Ranibizumab Intraocular-Zoledronic Acid (Zometa)
- Zoladex (Goserelin Implant 3.6 mg)-Ranibizumab ophthalmic
- Zoladex (Goserelin Implant 3.6 mg)-Ranitidine
- Zoladex (Goserelin Implant 3.6 mg)-Ranitidine Capsule
- Zoladex (Goserelin Implant 3.6 mg)-Ranitidine Hydrochloride
- Zoladex (Goserelin Implant 3.6 mg)-Ranitidine Injection
- Zoladex (Goserelin Implant 3.6 mg)-Ranitidine Suspension